Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Erbitux Sales Growth Will Bounce Back, Says Merck KGaA

This article was originally published in The Pink Sheet Daily

Executive Summary

Later-than-expected tenders in Europe and emerging clinical data are expected to allow sales of best-seller Erbitux to start growing again after an unexpected first-quarter decline, as the German company starts late-stage studies with PD-L1 inhibitor avelumab in its collaboration with Pfizer.

You may also be interested in...



Merck KGaA/SFJ's Abituzumab Evaluated For Left-Sided Metastatic Colon Cancer

SFJ Pharmaceuticals has taken on the late-stage clinical development of Merck KGaA's previously stalled MAb abituzumab, sharing the financial risk and evaluating patients with left-sided colorectal cancer.

Rossetti Sets A High Bar At Merck Serono

Once-moribund Merck Serono has hired former Merck R&D exec Luciano Rossetti to re-energize its attempts at an R&D turnaround. A deal with Pfizer for the PD-L1 inhibitor avelumab has the company off to a good re-start.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

UsernamePublicRestriction

Register

PS078505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel